mabthera sc rituximab (rch) 1400 mg/11.7 ml solution for injection vial
roche products pty ltd - rituximab, quantity: 1400 mg - injection - excipient ingredients: vorhyaluronidase alfa; histidine; histidine hydrochloride; trehalose dihydrate; methionine; polysorbate 80; water for injections - mabthera sc is indicated for treatment of patients with: - cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin's lymphoma, - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma, - cd 20 positive, diffuse large b-cell non-hodgkin's lymphoma, in combination with chemotherapy.
reopro- abciximab injection, solution
janssen biotech, inc. - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml - abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications - in patients undergoing percutaneous coronary intervention - in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours safety and efficacy of abciximab use in patients not undergoing percutaneous coronary intervention have not been established. abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in clinical studies. because abciximab may increase the risk of bleeding, abciximab is contraindicated in the following clinical situations: - active internal bleeding - recent (within six weeks) gastrointestinal (gi) or genitourinary (gu) bleeding of clinical significance - history of cerebrovascular accident (cva) within two years, or cva with a significant residual neurological deficit - bleeding diathesis - administration of oral anticoagulan
reopro abciximab injection solution
eli lilly and company - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml
mabthera 100mg10ml concentrate for solution for infusion vials
roche products ltd - rituximab - solution for infusion - 10mg/1ml
mabthera 500mg50ml concentrate for solution for infusion vials
roche products ltd - rituximab - solution for infusion - 10mg/1ml
erbitux 100mg20ml solution for infusion vials
merck serono ltd - cetuximab - solution for infusion - 5mg/1ml
erbitux 500mg100ml solution for infusion vials
merck serono ltd - cetuximab - solution for infusion - 5mg/1ml
mabthera 1400mg11.7ml solution for injection vials
roche products ltd - rituximab - solution for injection - 119.66mg/1ml
truxima 500mg50ml concentrate for solution for infusion vials
napp pharmaceuticals ltd - rituximab - solution for infusion - 10mg/1ml
truxima 100mg10ml concentrate for solution for infusion vials
napp pharmaceuticals ltd - rituximab - solution for infusion - 10mg/1ml